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Computational modeling of radiobiological effects in bone metastases for 
different radionuclides 
 
ABSTRACT 
Purpose: Computational simulation is a simple and practical way to study and to compare a variety of 
radioisotopes for different medical applications, including the palliative treatment of bone metastases. This 
study aimed to evaluate and compare cellular effects modelled for different radioisotopes currently in use or 
under research for treatment of bone metastases using computational methods. 
Methods: Computational models were used to estimate the radiation-induced cellular effects (Virtual 
Cell Radiobiology algorithm) post-irradiation with selected particles emitted by Strontium-89 (89Sr), 
Samarium-153 (153Sm), Lutetium-177 (177Lu), and Radium-223 (223Ra). 
Results: Cellular kinetics post-irradiation using 89Sr β- particles, 153Sm β− particles, 177Lu β− particles and 223Ra 
α particles showed that the cell response was dose- and radio- nuclide-dependent. 177Lu beta minus particles 
and, in particular, 223Ra alpha particles, yielded the lowest survival fraction of all investigated particles.  
Conclusions: 223Ra alpha particles induced the highest cell death of all investigated particles on metastatic 
prostate cells in comparison to irradiation with β− radionuclides, two of the most frequently used radionuclides 
in the palliative treatment of bone metastases in clinical routine practice. Moreover, the data obtained suggest 
that the used computational methods might provide some perception about cellular effects following irradiation 
with different radionuclides.   
 
Keywords: Computational simulation; Radiation-induced effects; Radium-223; Lutetium-177; Bone 
metastases. 
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I. INTRODUCTION 
Cancer is a major public health concern, and it is associated with significant morbidity and mortality. 
In 2012, approximately 14 million new cases were diagnosed, and 8 million cancer-related deaths occurred 
(Stewart & Wild 2014). Prostate cancer is the second most common cancer in men worldwide (Stewart & 
Wild 2014). A large percentage of patients with prostate cancer (65-75%) develop bone metastasis 
(Chakraborty et al. 2008; Maini et al. 2003; Bedi et al. 2014), which often leads to severe pain, hypercalcemia, 
lack of mobility and depression that adversely affect these patients’ life quality (Lewington 2005).  
Bone metastasis occurs as a result of a complex pathophysiologic process between host and tumour 
cells leading to cellular invasion, migration adhesion, and stimulation of osteoclastic or osteoblastic activity. 
The process is mediated by parathyroid hormones, cytokines and tumour-derived factors (Tantivejkul et al. 
2004; Roodman 2004; Roato 2013). 
There are several therapeutic approaches targeting bone metastases and associated effects, including 
the use of analgesics, external beam radiotherapy and radionuclide systemic therapy. The latter, systemic 
palliative targeted-therapy with suitable radiopharmaceuticals, has emerged as a particularly appealing and 
efficient treatment modality for patients with multiple skeletal metastases (Maini et al. 2003; Pandit-Taskar et 
al. 2014; Silberstein 1996; Pillai et al. 2003). 
Radionuclide therapy is characterized by reasonably selective delivery of therapeutic doses of radiation 
to systemically dispersed target tissues, with generally limited toxicity and few long-term side-effects (Unak 
2002). Bone-seeking radiopharmaceuticals have considerable advantages, including convenience, ability to 
treat multiple metastatic lesions simultaneously, and the possibility of combination with chemotherapeutic 
agents for enhanced efficacy. The basis of successful radionuclide therapy relies on a high concentration and a 
prolonged retention of the radiopharmaceutical at the tumour site. 
A major challenge associated with the palliative treatment of bone pain using selective 
radiopharmaceuticals is to deliver an adequate dose of ionizing radiation to the bone lesion, while minimizing 
the dose to healthy bone sites and adjacent tissues. In order or maximize the therapeutic effect and minimize 
normal-tissue irradiation, the radiation emitted by the targeted radionuclide should have an energy and tissue 
penetration range compatible with the volume of the lesion to be irradiated (Chakraborty et al. 2008; Wang et 
al. 2011). Therefore, studying the effects of particulate radiation at the cellular level is of interest to determine 
the suitability of a given radionuclide for target-tumor radiotherapy. There are essentially three main types of 
radioactive particles that are of interest for target-tumor radiotherapy: beta minus (β-) particles, alpha (α) 
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particles and Auger electrons. β- particles typically have a range of up to several millimeters in tissue, which 
may result in crossfire irradiation of cells adjacent to the targeted tumor. By contrast, α particles have a typical 
penetration range of less than 100 µm (Harrison et al. 2013). Auger electrons are low-energy electrons (typical 
energies around 20-100 keV) and have short penetration ranges only several nanometers to micrometers 
(Tavares & Tavares 2010). In addition to the physical properties of different radionuclides for target-tumor 
therapy, other characteristics should be taken into account while searching for the ideal radiopharmaceuticals 
for palliative treatment of bone metastases. For example, the radionuclide production costs and feasibility 
should be determined, and consideration should be given on whether its properties are amenable for 
radiochemistry procedures (Pillai et al. 2003). It is also important that the radionuclide to be used for palliative 
treatment of bone metastases allows for in vivo imaging, in order to assist with the determination of the suitable 
therapeutic dose to be used and to facilitate treatment monitoring (Henriksen et al. 2003; Pandit-Taskar et al. 
2014). 
In recent years, several reports have been published describing the use of Lutetium-177 (177Lu) in the 
context of palliative treatment of bone metastases (Chakraborty et al. 2008; Abbasi 2012; Bryan et al. 2009; 
Yuan et al. 2013; Máthé et al. 2010; Abbasi 2011; Liberal et al. 2014; Pillai & Knapp 2015). Moreover, 
Strontium-89 (89Sr), Samarium-153 (153Sm) and Radium-223 (223Ra) have already been approved by the Food 
and Drug Administration (FDA). The main physical characteristics of these radionuclides are indicted in Table 
I. 
 
< Table 1 should be inserted around here > 
 
32P was the first radioisotope to be evaluated for palliative treatment of bone metastases and its first 
clinical use dates back to 1941 (Bouchet et al. 2000). Presently, one of the most commonly used 
radionuclides for palliative treatment of bone metastases in routine clinical practice is 153Sm, which was 
approved by the FDA for clinical use in 1997 (Sartor 2004). 89Sr is also currently used in the clinical setting 
for alleviation of bone pain and it was approved by the FDA for clinical use in 1993 (Das et al. 2009). 
Recently, a significant amount of work has been carried out using 223Ra, a promising therapeutic agent for 
palliative treatment of bone metastases, in order to take advantage of the short tissue penetration range 
associated with its emitted α particles. In clinical studies, 223Ra has demonstrated a highly significant 
improvement on patient overall survival, with mild side effects owing to its localized tissue penetration (2-10 
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cells). Its clinical use was approved by the FDA in 2013 (Harrison et al. 2013). Another promising 
radionuclide recently proposed for palliative treatment of bone metastasis was 177Lu due to its appealing 
physical characteristics, in particular its half-life of 6.73 days, gamma ray emission of 113keV (6.4%) and 
208 keV (10.4%) and tissue penetration of 1.8 mm (Pillai et al. 2003; Dash et al. 2015).  
There is now sufficient evidence of the importance of bystander effect that can modify the biology of 
the un-irradiated cells, and have a strong impact on therapeutic efficacy (Boyd et al. 2006). Bystander effect 
will be in addition to the direct effects of radiation exposure; therefore, its contribution must also be taken 
into account. Incorporation of a bystander effect model could have profound implications on the design of 
radionuclide protocols (Prise & O’Sullivan 2009). However, in vivo experiments to investigate the bystander 
response in radionuclide therapy are far more challenging than in vitro or in silico experiments. 
Consequently, computational simulation may be used to study and to compare a variety of radioisotopes for 
different medical applications, including the palliative treatment of bone metastases, under the same 
investigation conditions and might provide some insight into the bystander effect. However, radiation-
induced effects are not yet fully understood, and regularly, new knowledge is added, consequently modelling 
cellular responses to irradiation is complex and challenging.  
The Virtual Cell (VC) algorithm is an ongoing effort that aims to understand tumor pathogenesis and 
treatment. Results from in silico testing using the VC simulator, relies on multiscale modelling that have been 
tested against a total of 23 in vitro datasets obtained using different cell types and exposure conditions. 
Results from that in silico versus in vitro comparison demonstrated that the simulated data obtained using the 
VC algorithm compared favorably with real-life measured data, so it is widely used by scientific community 
in few research articles (Liberal et al. 2014;. Tavares & Tavares 2010). 
This study aimed to use computational methods to evaluate and compare cellular effects modelled for 
different radioisotopes currently in use or under development for the palliative treatment of bone metastases, 
with regard to better understand the mechanisms that contribute to cell killing in each radionuclide at a wide 
range of absorbed doses and exposure time. Additionally, to infer how different outcomes, as mutagenic and 
genetic instability, neoplastic transformation and average number of direct lethal damage, relate to cell killing 
mechanism and no-direct effects, with special concern of bystander effect. In particular, the data reported 
here are focused on the bone metastases from the prostate carcinoma, given this is one of the most common 
types of cancer in men worldwide and the majority of these patients develop bone metastases. 
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II. METHODS 
The VC radiobiology simulator, was developed by Stewart and co-workers (Semenenko & Stewart 
2004), to evaluate the following cellular endpoints: cell death, neoplastic transformation, chromosome 
aberration yields, induction of genomic instability, cell cycle kinetics and the probability of tumour 
eradication following radiation therapy.  
Previous studies have shown that the 223Ra and 177Lu radiations induce the greatest number of 
deoxyribonucleic acid (DNA) lesions among all those investigated, with the lowest probability of correct 
repair of such lesions and the highest of induction of double-strand breaks (DSB) (Liberal et al. 2014). 
The Monte Carlo damage simulation (MCDS) algorithm was used to obtain the number DSB and the 
fraction of complex DSB (FCB) (Semenenko & Stewart 2004; Semenenko et al. 2005) for 89Sr, 153Sm, 177Lu, 
223Ra. The MCDS simulator is a fast Monte Carlo algorithm that models the damages to DNA by different 
particles and captures the major trends in the DNA damage spectrum predicted using detailed track structure 
simulations (Semenenko & Stewart 2004). The results obtained from the MCDS simulator (DSB and FCB) 
that yield the number of lesions caused by the radioactive particle to the DNA per Gy per cell were then 
applied as input parameters for the two-lesion kinetics (TLK) model used on the VC simulator. The 
approximate values of DSB and FCB obtained from the MCDS simulator for the evaluated particles 
were as follow: 89Sr β- particles, DSB = 50.055 and FCB = 0.1303; 153Sm β- particles, DSB = 49.631 and 
FCB = 0.1314; 177Lu β- particles, DSB = 50.430 and FCB = 0.1338; 223Ra α particles, DSB = 130.338 
and FCB = 0.4565. By inserting these parameters, required by the TLK model into the VC input file, the 
cellular exposure scenario modeled would mimic the isotope in close proximity to the cell nucleus. The TLK 
model was preferred over other radiation exposure models, such as the repair-misrepair model (RMR) and 
lethal-potentially lethal model (LPL), as it applies an improved correlation between the biochemical 
processes of DSB and cell death, by subdividing DSB into simple or complex DSBs (Sach et al. 1997; 
Guerrero et al. 2002; Semenenko & Stewart 2004). 
A comprehensive list with the input parameters used on the VC simulations is presented in the next 
section.  
 
II.A. Virtual Cell Simulator – Input Parameters 
In this section, only the key VC input parameters used for the present study are discussed in detail, 
since an online platform, including a comprehensive VC user guide, is freely available 
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(http://faculty.washington.edu/trawets/vc).  
The cell kinetics model (CKM) used was the quasi-exponential cell kinetics model (QECK), as that is 
the only available option for the current version of the VC simulator. Nonetheless, by using a high peak cell 
density (KAP) value (such as the one used in the present study, i.e. 1.0E+38 cells/cm3) and by selecting a 
small initial cell population (initial number of cells – N0 = 1000 cells) compared to KAP×VOL (where VOL 
= tissue volume = 1 cm3), the cell growth kinetics model becomes exponential. Furthermore, as the size of the 
cell population increases, the net cell birth rate decreases so that the cell population size approaches the 
asymptotic value KAP×VOL.  
A cell type was evaluated: human metastatic prostate cells (TPOT – cell doubling time = 54 days; TC 
– cell cycle time = 48 hours) (Berges et al. 1995). The evaluated populations were set to be quiescent (GF – 
growth fraction = 0) and all cells are cycling (GF = 1) in order to understand the radiobiological effects from 
the nuclides.  
The expected number of DSBs endogenously formed per cell-hour was defined as 4.3349E-03 Gy-1 
cell-1. The values of the biophysical parameters: repair half-time (RHT), pairwise damage interaction rate 
(ETA) and probability of correct repair (A0), were set according to the requisites of the selected damage 
repair model. For example, the used TLK model sets the RHT, ETA and A0 values at certain intervals, 
including those described in Table 1. The probability of misrejoined DSB being lethal (PHI) and the fraction 
of residual damage at the end of the simulation that is treated as lethal (FRDL) are adjustable parameters. The 
absolute residual damage cutoff (ACUT) value is also an adjustable parameter, and it terminates the 
simulation when the amount of unrepaired residual damage is less than the specified value. Residual damages 
include radiation-induced DNA damages that remain unrepaired due to (1) DNA damage that was too severe, 
(2) presence of damages in inaccessible parts of the genome, (3) induction of damages during critical points 
in the cell cycle or (4) DNA damages converted into large DNA deletions (McMillan 1992). It is reasonable 
to accept that after a certain level of residual damages, any further cellular killing can be neglected as non-
radiation related. The ACUT value of 1.0×10-9 expected number of DNA damages per cell was chosen based 
on the fact that it should be smaller than the spontaneous endogenous damages (established to be in the order 
of 10-3) and a value of zero would not terminate the simulation, since ACUT was the only simulation control 
parameter adopted in the present study. The fraction of binary-misrepaired damages that are lethal (GAM) 
was set at 0.25, because according to Sach and co-workers, around 1/4 of the chromosome aberrations formed 
through the pairwise interaction process are lethal (i.e., GAM = 0.25) (Sach et al. 1997). 
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The selected radiation exposure scenario was the exponentially decreasing dose rate (DECAY), since 
the present work aimed at modeling the cellular responses to different absorbed doses delivered by internal 
targeted radiotherapy using 4 radioisotopes: 89Sr, 153Sm, 177Lu and 223Ra. For each radioisotope investigated, 
a radioactive constant (LAM) and a radionuclide half-life (RHL) was set according to the well-known decay 
scheme of these radioisotopes. The average background absorbed dose rate on planet Earth (BGDR) has been 
quantified as 2.73748×10-7 Gy/h by the United Nations Scientific Committee on the Effects of Atomic 
Radiation (UNSCEAR) 2007 report (United Nations 2007). Irradiation periods of 2, 24, 48, 120 and 240 
hours (TCUT – time allowed for repair after exposure) with total absorbed doses delivered to the cell 
population over all time (TAD) of 0 .1, 0.5, 1, 2, 5 and 8 Gy were modeled using the VC simulator. The 
effective dose delivered to the cell system in a finite time interval (SAD) (0, TCUT), that is the SAD 
parameter is related to the TAD parameter by: SAD = (1-DCUT)×TAD, where DCUT = the dose cutoff used 
to truncate dose rate function after fraction 1-DCUT of total dose has been delivered. The DCUT is an 
adjustable parameter of the VC simulator and in this study it was set at 0.01, which means that the dose rate is 
truncated only after 99% of the set effective dose (SAD) has been delivered. This meant that SAD ≈ TAD. 
The use of the DCUT parameter is justifiable since at a given point, the activity of the radiation source 
becomes so small that any further radiation killing of the cell population can be neglected. The time to 
execute a DECAY simulation tends to increase as the number of steps increases. It is possible to control that 
by using the step-size tolerance (STOL) parameter, which typically ranges from about 0.05 to 1.0×10-3 Gy/h. 
As the STOL value decreases, the time requested to perform the simulation increases and thus a compromise 
between time and accuracy must be made. In the present study, a STOL value of 0.01 Gy/h was used.  
 
II.B. Data analysis 
The VC data were expressed as the number of direct lethal damages per surviving cell, estimated 
number of surviving cells, probability of mutagenesis and enhanced genetic instability per surviving cell, 
neoplastic transformation frequency per irradiated cell and neoplastic transformation frequency per surviving 
cell. Data differences among the investigated radioisotopes were analyzed using the analysis of variance 
(ANOVA) statistical test, where p < 0.01 was considered statically significant.  
 
III. RESULTS 
The cell survival fraction results obtained after irradiation with different radionuclides and particles are shown 
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in Fig. 1. The estimated survival fraction rank order of all investigated particles was as follows: 89Sr β− particles 
> 153Sm β− particles > 177Lu β− particles >> 223Ra α particles. Additionally, statistically significant differences 
were observed among the different irradiating agents (p < 0.0001, ANOVA) Moreover, statistical analysis 
revealed no differences among the results obtained for β− particles, when the 223Ra α particles data was 
excluded (p = 0.0252, ANOVA).  
 
< Figure 1 should be inserted around here > 
 
The estimated number of metastatic prostate cells that survived irradiation when all cells were 
quiescent and when all cells were actively dividing is presented in Figs. 2a and 2b, respectively. When all 
cells were quiescent, the estimated number of surviving cells is lower than the estimated number, for actively 
dividing cellular populations, for the same exposer conditions (Figs. 2a and 2b). Statistically significant 
differences were observed among these four different irradiating agents when metastatic prostate cells were 
quiescent and all cells were actively dividing (p < 0.0001, ANOVA).  
 
 < Figure 2 should be inserted around here > 
 
Figure 3 shows the mutagenesis and enhanced genetic instability probability per surviving cell for 
different irradiating sources. The analysis of these data reveals that the probability of mutagenesis and 
enhanced genetic instability of the cell population following irradiation with β− particles (89Sr, 153Sm, 177Lu) 
increased with the increase in absorbed doses, with exception for high absorbed doses (8.0 Gy) for short 
periods of time (≤ 24 h). On the other hand, the probability of mutagenesis and enhanced genetic instability of 
the cell population following irradiation with 223Ra α particles increased with the increase in exposure time 
and absorbed dose for values from 0.1 to 2 Gy; for absorbed doses higher than 2 Gy, the probability of 
mutagenic and enhanced genetic instability is negligible. Statistical analysis of the whole irradiation range 
reveals no differences among the results obtained with the different investigated particles (p = 0.534, 
ANOVA).  
 
< Figure 3 should be inserted around here > 
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The neoplastic transformation frequency per irradiated cell and per surviving cell for each evaluated 
particle are shown in Figs. 4a and 4b, respectively. The probability of neoplastic transformation per irradiated 
cell was highest for lower doses, regardless of the radioactive particle used, and reduced as the dose increased 
(Fig. 4a). Conversely, the probability of neoplastic transformation frequency per surviving cell was lowest for 
low absorbed doses and increased as the absorbed dose increased for 223Ra α particles and constant whole 
irradiation range for β− particles (89Sr, 153Sm, 177Lu) (Fig. 4b). The reduction rates of neoplastic 
transformation frequency per irradiated cell varied for low- and high-LET (linear energy transfer) particles, 
where the steepest reduction was observed for high-LET particles, and a slower reduction was found for low-
LET particles. Statistically significant differences were observed among distinct radioactive particle 
neoplastic transformation frequencies per irradiated cell (p < 0.0001, ANOVA).  
 
< Figure 4 should be inserted around here > 
 
Finally, Fig. 5 shows the number of direct lethal damages per surviving cell as a function of absorbed 
dose. The results showed a rapid increase in cellular lethal damages as the absorbed dose increased for all the 
exposed periods tested, and statistically significant differences were observed among the results using distinct 
particles (p = 0.002, ANOVA). 
 
< Figure 5 should be inserted around here > 
 
IV. DISCUSSION AND CONCLUSION 
The results showed that the cell survival fraction decreased as a function of absorbed dose and 
increases as function of exposure time. The 223Ra α particles had the lowest survival fraction of all 
investigated irradiating agents in all irradiation scenarios, suggesting that these irradiating agents would be 
more promising in the killing of metastatic cells than the other investigated irradiating agents (Fig. 1). 
Moreover, that the cell response appears to behave in a LET and dose dependent manner  
To further clarify the nature of the cell response following irradiation with different particles, three 
cellular endpoints were assessed by computational simulation mutagenesis and enhanced genetic instability 
per surviving cell (Fig. 3), neoplastic transformation per irradiated or surviving cell (Fig. 4) and number of 
direct lethal damages per surviving cell (Fig. 5). Cellular endpoints are usually associated with the bystander 
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effect (Lyng et al. 2002; Mothersill & Seymour 2003; Nagasawa et al. 2003; Prise & O’Sullivan 2009). 
Our findings, obtained by means of computational simulators, indicated that the most promising agent 
for palliative treatment of bone metastases from prostate cancer is the 223Ra α particles that offer a therapeutic 
advantage over the β− radionuclides due to the higher capacity of inducing lethal damage and greater 
bystander effect at low-to-moderate doses. Other commonly used radioisotopes for palliative treatment of 
bone metastases, such as 89Sr, were found to be inferior in inducing lethal damages than 177Lu or 223Ra.  
Detailed analysis of the cellular kinetics post-irradiation using 89Sr β- particles, 153Sm β− particles, 
177Lu β− particles and 223Ra α particles showed that the cell response was dose- and radio- nuclide-dependent. 
For short TCUTs (≤ 48 h), virtually no differences were found between all β- particles. Conversely, for long 
TCUTs (≥ 120 h) on metastatic populations at low absorbed doses (0.1 and 0.5 Gy) all radiation sources 
tested were equivalently able to induce cell death. And at high-absorbed doses (≥1 Gy), irradiation with 223Ra 
α particles resulted in a lower number of surviving cells followed by 153Sm β− particles, 177Lu β− particles and 
89Sn β− particles. 
Our findings also showed that a larger number of actively dividing cells survived irradiation when 
compared with quiescent cells. This observation highlights the influence of cell kinetics on cell response to 
irradiation. We hypothesize that due the shorter doubling time (54 days) of metastatic prostate cells the 
unaffected cells were able to compensate radiation-induced damage by rapid cell duplication when all 
population were actively dividing. 
Mutagenesis and enhanced genetic instability results showed that there is a non-linear relationship 
between genomic instability and absorbed dose (Fig. 3). Sokolov and co-workers in 2005, using primary 
human fibroblasts, found that for doses of alpha particles and gamma rays between 0.2 and 0.6 Gy, the 
number of DSB sites in bystander cells was higher than for doses of 2.0 Gy (Sokolov et al. 2005). DNA 
DSBs have been associated with genetic instability, which is one of the mechanisms underlying the bystander 
effect. Moreover, Boyd and co-workers in 2006, showed dose-response relationship for the indirect effects 
produced by cellular exposure with low-LET β− radionuclides, using human glioma cells and human bladder 
carcinoma cells (Boyd et al. 2006). The results from the VC simulator showed that the probability of 
mutagenesis and genetic instability for 223Ra α particles was higher for doses ranging between 0.1 and 1 Gy 
than for doses equal to or above 2 Gy (Fig. 3). These findings seem to be in line with in vitro observations 
reported by Sokolov and co-workers in 2005 (Sokolov et al. 2005) and Boyd and co-workers in 2006 (Boyd 
et al. 2006).  
	 12	
The data also showed that the probability of cell transformation per irradiated cell was higher for 
lower absorbed doses (Fig. 4a), while the probability of cell transformation per surviving cell (Fig. 4b), and 
the number of direct lethal damages per surviving cell (Fig. 5) was higher for high absorbed doses. Redpath 
and co-workers studies have also reported that the cell transformation frequency per surviving cell increased 
with increasing absorbed doses (Redpath & Elmore 2007; Redpath 2006). Results from the VC simulator are 
in line with these prior observations. The increasing probability of cell transformation per surviving cell with 
increasing absorbed doses means that the normal cells surrounding the tumor have to be protected when 
performing target tumor radiotherapy, particularly for high doses of radiation.  
Taken all together, the data show that, at the lower absorbed doses, the transformation frequency per 
irradiated cell when exposure with an β- emitter radionuclide and genetic instability of surviving cells when 
exposure to an α emitter radionuclide are major contributors for the low number of estimated surviving cells, 
since the values of direct lethal damages and transformation frequency per surviving cell for lower doses are 
small compared with higher absorbed doses. Conversely, at higher absorbed doses, cell death is mainly 
related to the number of direct lethal damages, the transformation frequency per surviving cell and the 
radiation quality. This does not mean that genetic instability of surviving cells and transformation frequency 
per irradiated cell effects have no relevance at higher doses, but that their relative importance as a portion of 
the total effect tends to decrease as the dose increases. 
The data obtained from the VC simulator should be interpreted with caution due to the parameter 
estimation issues associated with mechanism-based radiation response models. Although flexibility in 
changing input parameters will have obvious advantages by allowing the modeling of multiple irradiation 
scenarios, it also represents an issue due to the uncertainty associated with the somewhat arbitrary choice of a 
certain value for a give parameter. Together with in vitro or in vivo studies data, simulators such as the one 
adopted in this work, would allow better experimental design and could be used to study different processes 
associated with cell response to ionizing radiation.  
Computational simulation is widely recognized as an essential method to study the physics of 
radiobiology. Nevertheless, some limitations have been pointed out, including modeling and evaluation based 
on current knowledge, which works as a mechanistic process. Furthermore, the computational algorithms 
used in this study only model simple repair processes and exclude DSBs repair processes. Moreover, the used 
algorithms assume an optimal scenario of ionizing energy deposition directly into the DNA, scenario that 
often is challenging to achieve in vitro and in vivo due to inefficient radiopharmaceutical biodistribution 
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processes, and assume that the radioactivity was distributed uniformly throughout the target. However, there 
have been dramatic improvements in dosimetry models and simulators that reflect the substructure of target 
and elements within them (Vaziri et al. 2014). Consequently, future in vitro and in vivo studies are crucial to 
establish a definite role of the simulator used here and careful interpretation of the results is therefore 
recommended. Nevertheless, the comparative analysis of the VC generated data with prior studies support the 
use of the VC simulator as a useful tool in the field of radiobiology, with particular utility in the context of 
radiotherapy. 
The radioisotopes studied included β emitters and α emitters, covering the most commonly used 
particles in current targeted tumor radiotherapy in bone metastases. Doses ranging between 0.1 and 8.0 Gy 
were tested on quiescent and actively dividing cell populations and the number of surviving cells following 
irradiation was estimated. The VC simulator is a user-friendly platform that provides output data consistent 
with experimental terminology used by cellular radiobiologists. This might foster the future use of the VC 
simulator by non-computer scientists, by using a similar approach as the one described here.  
In conclusion, the data obtained using the VC simulator indicate that for doses below 0.1Gy all tested 
particles (89Sr β− particles, 153Sm β− particles, 177Lu β− particles, 223Ra α particles) seem to be equally able to 
induce cell death independently of their LET. At low doses, cell death was found to be due to high genetic 
instability and cell transformation that are cellular end-points measured when investigating the bystander 
effect. On the contrary, at high-absorbed doses, cellular response to radiation seems to be dose and LET 
dependent.  
223Ra α particle emission is an appealing strategy for the treatment of bone micrometastases, owing to 
the short tissue range penetration associated with these radioactive particles that can allow for a more 
circumscribed irradiation surface. Furthermore, typically α emitters induce less hematologic toxicity for a 
given bone surface dose than β− emitters (Pandit-Taskar et al. 2014; Harrison et al. 2013; Nilsson et al. 2013). 
The high linear energy transfer of α particles has been associated with greater biological effectiveness than 
that of β− particles (Pandit-Taskar et al. 2014; Harrison et al. 2013; Nilsson et al. 2013). 223Ra-dichloride has 
been shown to not only have a palliative effect but also a survival prolonging effect (Harrison et al. 2013; 
Nilsson et al. 2013).  
Among the β− particle emitters, the 177Lu has the lowest tissue penetration range (1.8 mm). A common 
concern associated with the use of β− particle is related to their relatively long range in tissue, which can 
result in energy deposition in neighboring, nontargeted cells, a phenomenon known as “cross-fire” that may 
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lead to excessive bystander effects. With α particle emitters, due to their short tissue penetration range, the 
cross fire effect is not such a concern, but may require targeting virtually every cell within large size tumors 
and does not take advantage of the positive bystander effects (Jackson et al. 2013). The relatively short range 
of 177Lu β− particles in tissues is at the lower end of the β− particle generally, thereby minimizing the potential 
adverse effects cross-fire often associated with β− particle emitters. Also, it is higher than typical α particles 
allowing us to take advantage of the positive bystander effects that are not attainable with conventional α 
particles emitters.  
Notwithstanding, previously published data have shown that the 223Ra α particles have an increased 
antitumor effect when compared with β− particles (Nilsson et al. 2005; Pandit-Taskar et al. 2014; Nilsson et 
al. 2013). This might explain recent data demonstrating that 223Ra was the first agent in its class to show an 
overall survival advantage in patients with bone metastases from prostate carcinomas (Goyal & Antonarakis 
2012). In line with these observations, our analysis showed a superiority of the 223Ra α particles compared 
with the modeled β− particles. In particular, the clinical outcome of a given therapeutic depends not only on 
the cellular response but also on, for example, the individual patient differences in clinical conditions, patient 
preparation, life-expectancy, age, and the existence of secondary tumors. Furthermore, radiopharmaceuticals 
biodistribution, elimination, and concentration in the biological target tissue in vivo would also impact 
therapeutic response.  
In conclusion, this study compared different irradiating agents using the same exposure conditions and 
controllable cell populations to clarify the radiobiological effects of these radioisotopes for palliative 
treatment of bone metastases, specifically in the context of prostate cancer. The top agent able to induce the 
highest cellular damage and cell death was found to be the 223Ra α particles. 223Ra-dichloride is a particularly 
appealing approach for the treatment of bone metastases based on the data reported here, radionuclide 
physical properties, suitable production methods and feasible logistics of distribution. Within the β− particle 
emitters investigated, 177Lu was the preferred one due its adequate half-life and physical properties for image 
acquisition. There is much still to understand with regard to the differences biological processes that underpin 
the differences in behavior of high- and low-LET radionuclides. However, the data obtained suggest that the 
computational methods used might provide some insight into cellular effects following irradiation. Although, 
in vitro and in vivo data are necessary to support our findings and clarifies how much the contribution of the 
in lethality is owing to a direct effect and what component of it is owing to bystander effect for each 
radionuclide and scenario, the VC simulator can be useful as a first screening tool for predicting and 
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modelling cellular effects and the bystander effect due to the close association found between genetic 
instability, cell transformation and the bystander effect. 
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TABLE AND FIGURES  
Table I: Summary of main physical properties of different radionuclides in clinical use or under research for 
palliative treatment of bone metastases. 
Radionuclide 
Emission 
Type 
Emean (MeV) (%) 
Eγ (keV) 
(%) 
T1/2 
(days) 
Tissue 
penetration 
range (mm) 
Auger Transition 
– Average Energy 
(keV) (%) 
References  
89Sr β
- 
0.5846    
(99.99) 
909 
(0.1) 
50.5 6.7 ------- 
(Bé et al. 2008; 
Lewington 2005; 
Volkert & Hoffman 
1999) 
153Sm β
- 
0.2253    
(48.2) 
103 
(28) 
1.93 3.4 34 (4.6) 
(Bé et al. 2008; 
Lewington 2005; 
Volkert & Hoffman 
1999) 
177Lu β
- 
0.1494    
(79.3) 
211 
(11) 
6.2 1.8 6 (9) 
(Bé et al. 2008; Volkert 
& Hoffman 1999) 
223Ra α 
5.71581  
(45.6) 
154 
(5.6) 
11.4 0.1 62 (1.7) 
(Bé et al. 2008; 
Lewington 2005; 
Henriksen et al. 2003) 
Legend: T1/2 (days) – radioisotope half-life in days; E (MeV) (%) – particle energy and respective decay abundance 
shown in parentheses; Eγ (KeV) (%) – gamma ray energy and respective abundance in total energy emission shown in 
parentheses; Tissue penetration range (mm) – maximum tissue penetration in soft tissue shown in millimeters; Auger 
Transition – Average Energy (keV) (%) – average Auger transition energy and respective abundance shown in 
parentheses. 
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Figure	1:	Cell survival fraction estimated for 89Sr, 153Sm, 177Lu and 223Ra. 
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Figure	2:	Number	of	metastatic	prostate	cells	that	survive	irradiation	with	different	irradiating	agents	in	a	quiescent	cell	population	 (a),	 and	 in	 cells	 actively	dividing	 (b).	 (Simulated	doses	of	0.1,	0.5,	1,	 2,	 5,	 and	8	Gy	and	 irradiation	periods	of	2,	24,	48,	120,	and	240	h.)	
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Figure	 3:	 Mutagenesis and enhanced genetic instability probability per surviving cell for different irradiating 
sources: whole irradiation range. 
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Figure	4:	Neoplastic	transformation	frequency	per	irradiated	cell	(a)	and	per	surviving	cell	(b),	following	exposure	to	different	radiation	sources	and	distinct	absorbed	doses.		
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Figure	5:	Average number of direct lethal damages per surviving cell after irradiation with distinct particles and different 
irradiation scenarios in a logarithmic scale. 	
 
